Immunogenic cell death in colon cancer prevention and therapy

Colorectal cancer (CRC) is a leading cause of cancer‐related death worldwide. The colonic mucosa constitutes a critical barrier and a major site of immune regulation. The immune system plays important roles in cancer development and treatment, and immune activation caused by chronic infection or inflammation is well‐known to increase cancer risk. During tumor development, neoplastic cells continuously interact with and shape the tumor microenvironment (TME), which becomes progressively immunosuppressive. The clinical success of immune checkpoint blockade therapies is limited to a small set of CRCs with high tumor mutational load and tumor‐infiltrating T cells. Induction of immunogenic cell death (ICD), a type of cell death eliciting an immune response, can therefore help break the immunosuppressive TME, engage the innate components, and prime T cell‐mediated adaptive immunity for long‐term tumor control. In this review, we discuss the current understanding of ICD induced by antineoplastic agents, the influence of driver mutations, and recent developments to harness ICD in colon cancer. Mechanism‐guided combinations of ICD‐inducing agents with immunotherapy and actionable biomarkers will likely offer more tailored and durable benefits to patients with colon cancer.

[1]  H. Lenz,et al.  Molecular insight of regorafenib treatment for colorectal cancer. , 2019, Cancer treatment reviews.

[2]  D. Goodlett,et al.  The Role of TLRs in Anti-cancer Immunity and Tumor Rejection , 2019, Front. Immunol..

[3]  Wei Yang,et al.  MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway , 2019, Oncogene.

[4]  Chin Liang Lee,et al.  Virotherapy: Current Trends and Future Prospects for Treatment of Colon and Rectal Malignancies , 2019, Cancer investigation.

[5]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[6]  Jaeho Bae,et al.  Upregulation of Myc promotes the evasion of NK cell-mediated immunity through suppression of NKG2D ligands in K562 cells , 2019, Molecular medicine reports.

[7]  Rachel E. Brewer,et al.  CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy , 2019, Nature.

[8]  J. Luke,et al.  STING pathway agonism as a cancer therapeutic , 2019, Immunological reviews.

[9]  G. Del Favero,et al.  First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. , 2019, Metallomics : integrated biometal science.

[10]  M. Diederich.  Natural compound inducers of immunogenic cell death , 2019, Archives of Pharmacal Research.

[11]  Zhengfan Jiang,et al.  Apoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and IRF3. , 2019, Molecular cell.

[12]  R. DePinho,et al.  KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. , 2019, Cancer cell.

[13]  A. Ploss,et al.  Decoding type I and III interferon signalling during viral infection , 2019, Nature Microbiology.

[14]  C. Swanton,et al.  Resolving genetic heterogeneity in cancer , 2019, Nature reviews genetics.

[15]  D. Olson,et al.  The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development. , 2019, Immunotherapy.

[16]  Jian Yu,et al.  BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5. , 2019, Cancer research.

[17]  J. Luke,et al.  WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers , 2019, Clinical Cancer Research.

[18]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[19]  S. Barry,et al.  PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity , 2018, Journal of Immunotherapy for Cancer.

[20]  E. Chu,et al.  Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non‐MSI‐H Metastatic Colorectal Cancer , 2018, Clinical colorectal cancer.

[21]  M. Schaffer,et al.  Radiation therapy and immunotherapy-a potential combination in cancer treatment. , 2018, Current oncology.

[22]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[23]  Benjamin J. Raphael,et al.  Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer , 2018, Systems Immuno-Oncology.

[24]  J. Luke,et al.  T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection , 2018, Cancer Immunology Research.

[25]  L. Cantley,et al.  The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment , 2018, Cell.

[26]  S. M. Toor,et al.  DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer , 2018, Clinical Epigenetics.

[27]  Q. Wang,et al.  Treatment of colon cancer with liver X receptor agonists induces immunogenic cell death , 2018, Molecular carcinogenesis.

[28]  Lei Zhou,et al.  Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer. , 2018, Molecular medicine reports.

[29]  Jian Yu,et al.  Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. , 2018, Cancer research.

[30]  Vinícius Andrade-Oliveira,et al.  Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response , 2018, Oncotarget.

[31]  Jian Yu,et al.  Immunogenic effects of chemotherapy-induced tumor cell death , 2018, Genes & diseases.

[32]  James A. Eddy,et al.  The Immune Landscape of Cancer. , 2018, Immunity.

[33]  Jian Yu,et al.  Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer , 2018, Oncogene.

[34]  B. Helmink,et al.  The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.

[35]  S. Son,et al.  Elimination of established tumors with nanodisc-based combination chemoimmunotherapy , 2018, Science Advances.

[36]  M. Kloor,et al.  Complex pattern of immune evasion in MSI colorectal cancer , 2018, Oncoimmunology.

[37]  Jian Yu,et al.  PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors , 2018, Proceedings of the National Academy of Sciences.

[38]  K. D. de Visser,et al.  Cancer‐Cell‐Intrinsic Mechanisms Shaping the Tumor Immune Landscape , 2018, Immunity.

[39]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[40]  Jian Yu,et al.  Colorectal cancer prevention: Immune modulation taking the stage. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[41]  J. Mulé,et al.  Suppression of STING Signaling through Epigenetic Silencing and Missense Mutation Impedes DNA-Damage Mediated Cytokine Production , 2018, Oncogene.

[42]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[43]  Lieping Chen,et al.  DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune cell activation , 2018, Nature Medicine.

[44]  G. Evan,et al.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.

[45]  S. Fröhling,et al.  Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors , 2017, Genes, chromosomes & cancer.

[46]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[47]  S. Baylin,et al.  Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells , 2017, PloS one.

[48]  Jian Yu,et al.  FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors , 2017, Molecular Cancer Therapeutics.

[49]  C. Thompson,et al.  Nutrient acquisition strategies of mammalian cells , 2017, Nature.

[50]  Jian Yu,et al.  Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. , 2017, Cancer research.

[51]  O. Finn.  Human Tumor Antigens Yesterday, Today, and Tomorrow , 2017, Cancer Immunology Research.

[52]  I. Weissman,et al.  A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer , 2017, Nature Communications.

[53]  Theresa A. Storm,et al.  Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors , 2017, Science Translational Medicine.

[54]  Amy R. Peck,et al.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. , 2017, Cancer cell.

[55]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[56]  S. Albelda,et al.  CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.

[57]  Jian Yu,et al.  Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress , 2016, OncoTarget.

[58]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[59]  J. Medema,et al.  Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation. , 2016, Trends in cancer.

[60]  T. Gajewski,et al.  The host STING pathway at the interface of cancer and immunity. , 2016, The Journal of clinical investigation.

[61]  Jian Yu,et al.  BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells , 2016, Oncotarget.

[62]  Jian Yu,et al.  FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation , 2016, Oncogene.

[63]  L. Ricciardiello,et al.  Chemoprevention of hereditary colon cancers: time for new strategies , 2016, Nature Reviews Gastroenterology &Hepatology.

[64]  A. Bardelli,et al.  The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death , 2016, Nature Medicine.

[65]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[66]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[67]  Jian Yu,et al.  Necroptosis: an alternative cell death program defending against cancer. , 2016, Biochimica et biophysica acta.

[68]  M. Kloor,et al.  The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.

[69]  M. Beckmann,et al.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2016, Cell.

[70]  Yin Cao,et al.  Aspirin and colorectal cancer: the promise of precision chemoprevention , 2016, Nature Reviews Cancer.

[71]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[72]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[73]  G. Semenza,et al.  HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells , 2015, Proceedings of the National Academy of Sciences.

[74]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[75]  J. Galon,et al.  From mice to humans: developments in cancer immunoediting. , 2015, The Journal of clinical investigation.

[76]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[77]  Jian Yu,et al.  Abstract 667: Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis , 2015 .

[78]  L. Galluzzi,et al.  eIF2α phosphorylation as a biomarker of immunogenic cell death. , 2015, Seminars in cancer biology.

[79]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[80]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[81]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[82]  Jian Yu,et al.  Loss of Caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis , 2015, Cell Death and Disease.

[83]  Satoshi Hirano,et al.  The key role of calreticulin in immunomodulation induced by chemotherapeutic agents , 2015, International Journal of Clinical Oncology.

[84]  P. Hwu,et al.  BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma , 2015, Cancer Immunology Research.

[85]  Jian Yu,et al.  mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction upon 4E-BP1 dephosphorylation , 2015, Oncogene.

[86]  H. Udono,et al.  Immune-mediated antitumor effect by type 2 diabetes drug, metformin , 2015, Proceedings of the National Academy of Sciences.

[87]  Jian Yu,et al.  BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs , 2014, Proceedings of the National Academy of Sciences.

[88]  Lin Zhang,et al.  Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer , 2014, Genes & diseases.

[89]  Mark T Lee,et al.  Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. , 2014, Anticancer research.

[90]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[91]  P. Vandenabeele,et al.  Consensus guidelines for the detection of immunogenic cell death , 2014, Oncoimmunology.

[92]  J. Galon,et al.  Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014 .

[93]  J. Meyerhardt,et al.  Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. , 2014, Journal of the National Cancer Institute.

[94]  P. Vandenabeele,et al.  Regulated necrosis: the expanding network of non-apoptotic cell death pathways , 2014, Nature Reviews Molecular Cell Biology.

[95]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[96]  Jian Yu,et al.  Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention , 2013, Current Colorectal Cancer Reports.

[97]  Jian Yu,et al.  Hsp90 Inhibitors Promote p53-Dependent Apoptosis through PUMA and Bax , 2013, Molecular Cancer Therapeutics.

[98]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[99]  R. Wolff,et al.  Interleukin genes and associations with colon and rectal cancer risk and overall survival , 2013, International journal of cancer.

[100]  Martha L Slattery,et al.  JAK/STAT/SOCS‐signaling pathway and colon and rectal cancer , 2013, Molecular carcinogenesis.

[101]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[102]  Michael A. Davies,et al.  Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.

[103]  O. Finn,et al.  Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  Jian Yu,et al.  The Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA , 2012, PloS one.

[105]  P. Tassone,et al.  Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients , 2012, Journal of immunotherapy.

[106]  A. Möller,et al.  CD73-deficient mice are resistant to carcinogenesis. , 2012, Cancer research.

[107]  M. Marra,et al.  Cetuximab ± chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cell response in vitro , 2012, International journal of cancer.

[108]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[109]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[110]  B. Martín-Castillo,et al.  Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation , 2012, Cell cycle.

[111]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[112]  William J. Kaiser,et al.  Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways , 2011, Nature Reviews Immunology.

[113]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[114]  R. Binder,et al.  CD91-dependent programming of T-helper cell responses following heat shock protein immunization. , 2011, Nature communications.

[115]  R. Wolff,et al.  Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. , 2011, Carcinogenesis.

[116]  D. Green,et al.  RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. , 2011, Molecular cell.

[117]  Vanesa Fernández-Majada,et al.  FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation , 2011, Nature.

[118]  A. Strasser,et al.  Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases , 2011, The EMBO journal.

[119]  Helmut Neumann,et al.  Caspase-8 regulates TNF-alpha induced epithelial necroptosis and terminal ileitis , 2011, Nature.

[120]  H. Seno,et al.  COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. , 2011, Carcinogenesis.

[121]  M. Pino,et al.  Microsatellite instability in the management of colorectal cancer , 2011, Expert review of gastroenterology & hepatology.

[122]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[123]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[124]  R. Hakem,et al.  RIP3 mediates the embryonic lethality of caspase-8-deficient mice , 2011, Nature.

[125]  L. Zitvogel,et al.  TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. , 2011, Cancer research.

[126]  D. Ron,et al.  Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress , 2011, Nature Cell Biology.

[127]  C. Tinelli,et al.  Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer , 2011, Oncology.

[128]  H. Bessler,et al.  Inflammation and Colorectal Cancer: Does Aspirin Affect the Interaction between Cancer and Immune Cells? , 2011, Inflammation.

[129]  Allon M Klein,et al.  Intestinal Stem Cell Replacement Follows a Pattern of Neutral Drift , 2010, Science.

[130]  Jian Yu,et al.  Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis , 2010, Proceedings of the National Academy of Sciences.

[131]  G. Kroemer,et al.  Autophagy and the integrated stress response. , 2010, Molecular cell.

[132]  Hans Clevers,et al.  Intestinal Crypt Homeostasis Results from Neutral Competition between Symmetrically Dividing Lgr5 Stem Cells , 2010, Cell.

[133]  C. Müller,et al.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. , 2010, Gastroenterology.

[134]  Hirokazu Takahashi,et al.  Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial , 2010, Cancer Prevention Research.

[135]  A. Schwab,et al.  Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis , 2010, Science Signaling.

[136]  J. Marshall,et al.  Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents , 2010, Gastrointestinal cancer research : GCR.

[137]  M. Moyer,et al.  Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis , 2010, Nature.

[138]  Jian Yu,et al.  Mitochondrial signaling in cell death via the Bcl-2 family , 2010, Cancer biology & therapy.

[139]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[140]  A. Grothey,et al.  Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.

[141]  H. Kestler,et al.  p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice , 2009, Nature Genetics.

[142]  D. Green,et al.  Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.

[143]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[144]  P. van Endert,et al.  Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.

[145]  S. Lippman.  The future of molecular-targeted cancer chemoprevention. , 2008, Gastroenterology.

[146]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[147]  Alexei Degterev,et al.  Expansion and evolution of cell death programmes , 2008, Nature Reviews Molecular Cell Biology.

[148]  Jane J. Sohn,et al.  Helicobacter hepaticus Infection Promotes Colon Tumorigenesis in the BALB/c-Rag2−/−ApcMin/+ Mouse , 2008, Infection and Immunity.

[149]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[151]  S. Jagannath,et al.  Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. , 2007, Blood.

[152]  L. Staudt,et al.  c‐MYC activation impairs the NF‐κB and the interferon response: Implications for the pathogenesis of Burkitt's lymphoma , 2007, International journal of cancer.

[153]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[154]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[155]  J. Meyerhardt,et al.  Systemic therapy for colorectal cancer. , 2005, The New England journal of medicine.

[156]  Jian Yu,et al.  Apoptosis in human cancer cells , 2004, Current opinion in oncology.

[157]  Jian Yu,et al.  Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells , 2003, Cancer biology & therapy.

[158]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[159]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[160]  A. Ohta,et al.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.

[161]  H. Clevers,et al.  Mutations in the APC tumour suppressor gene cause chromosomal instability , 2001, Nature Cell Biology.

[162]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[163]  K. Kinzler,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[164]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[165]  E. Papavassiliou,et al.  Aspirin and aspirin-like drugs induce HLA-DR expression in HT29 colon cancer cells. , 1996, International journal of oncology.

[166]  C. Atreya,et al.  Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[167]  O. Finn,et al.  Cancer immunoprevention. , 2016, Current opinion in immunology.

[168]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[169]  K. Lundholm,et al.  Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. , 2008, Cancer immunity.

[170]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[171]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.